Table 5.
Subsequent treatment after progression.
| Combination Group | TACE Group | |
|---|---|---|
| (N = 42) No. (%) | (N = 41) No. (%) | |
| Accepted Subsequent Treatments | 23 (54.8) | 31 (75.6) |
| Lenvatinib+PD-1 inhibitor | 14 (33.3) | 0 |
| Apatinib+PD-1 inhibitor | 4 (9.5) | 0 |
| Apatinib | 3 (7.1) | 2 (4.9) |
| Radiotherapy +PD-1 inhibitor | 1 (2.4) | 1 (2.4) |
| Ablation+ PD-1 inhibitor | 1 (2.4) | 0 |
| Sorafenib | 0 | 5 (12.2) |
| TACE | 0 | 18 (43.9) |
| Radiotherapy | 0 | 2 (4.9) |
| TACE+Radiotherapy | 0 | 3 (7.3) |
| Best Supportive Care | 19 (45.2) | 10 (24.4) |
The bold values highlighted the factors with significant difference.
Data are presented as n (%).
TACE, transcatheter arterial chemoembolization; PD-1, programmed cell death-1.